利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.023 秒)

    Anti-human IL-21 monoclonal antibodies
    2.
    发明公开
    Anti-human IL-21 monoclonal antibodies 有权
    Monoklonale抗人IL-21-Antikörper

    公开(公告)号：EP2426146A2

    公开(公告)日：2012-03-07

    申请号：EP11185989.8

    申请日：2008-12-08

    申请人： ZymoGenetics, Inc.

    发明人： Jaspers, Stephen R. ,  Rixon, Mark W. ,  Dillon, Stacey R. ,  Ramsdell, Frederick J. ,  Krejsa, Cecile M. ,  Yi, Eugene C.

    IPC分类号： C07K16/24

    CPC分类号： C07K16/244 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  Y10S530/809

    摘要： There is provided an anti-human IL-21 monoclonal antibody comprising: (a) a heavy chain region comprising: (i) a heavy chain variable region CDR1 comprising SEQ ID NO: 63; (ii) a heavy chain variable region CDR2 comprising SEQ ID NO: 65; and (iii) a heavy chain variable region CDR3 comprising SEQ ID NO: 67; and (b) a light chain region comprising: (i) a light chain variable region CDR1 comprising SEQ ID NO: 71; (ii) a light chain variable region CDR2 comprising SEQ ID NO: 73; and (iii) a light chain variable region CDR3 comprising SEQ ID NO: 75. There is also provided a hybridoma designated 366.328.10, wherein the hybridoma is deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-8789.

    摘要翻译： 提供抗人IL-21单克隆抗体，其包含：（a）重链区，其包含：（i）包含SEQ ID NO：63的重链可变区CDR1; （ii）包含SEQ ID NO：65的重链可变区CDR2; 和（iii）包含SEQ ID NO：67的重链可变区CDR3; 和（b）轻链区，其包含：（i）包含SEQ ID NO：71的轻链可变区CDR1; （ii）包含SEQ ID NO：73的轻链可变区CDR2; 还提供了包含SEQ ID NO：75的轻链可变区CDR3。还提供了称为366.328.10的杂交瘤，其中杂交瘤保藏在具有ATCC专利保藏号PTA-8789的美国典型培养物保藏中心。

    Method for treating inflammation
    3.
    发明公开
    Method for treating inflammation 有权
    Verfahren zur Behandlung vonEntzündungen

    公开(公告)号：EP1743648A1

    公开(公告)日：2007-01-17

    申请号：EP06006242.9

    申请日：2000-12-22

    申请人： ZymoGenetics, Inc.

    发明人： Thompson, Penny ,  Foster, Donald C. ,  Wenfeng, Xu ,  Madden, Karen L. ,  Kelly, James D. ,  Sprecher, Cindy A. ,  Blumberg, Hal ,  Eagen, Maribeth A. ,  Jaspers, Stephen R. ,  Chandrasekher, Jasmin A. ,  Novak, Julia E.

    IPC分类号： A61K38/17 ,  C07K14/54 ,  C07K19/00 ,  A61P1/00 ,  A61P11/06 ,  A61P19/02 ,  A61P35/00 ,  A61P37/00 ,  A61P31/00 ,  C07K14/715

    CPC分类号： C07K14/7155 ,  A61K38/00 ,  A61K38/20 ,  C07K16/244 ,  C07K2319/30

    摘要： The use is provided of a soluble receptor that binds to an IL-20 polypeptide, wherein the IL-20 polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8 and 9, for the manufacture of a medicament for treating an inflammatory disease, wherein said soluble receptor comprises: a first subunit, said first subunit comprising an amino acid sequence selected from SEQ ID NOs: 11, 12, 55, 63 and 65, or a fragment thereof that binds to an IL-20 polypeptide; and a second subunit, said second subunit comprising an amino acid sequence selected from SEQ ID NOs: 14, 15, 19, 59, 61, 67, 68 and 69, or a fragment thereof that binds to an IL-20 polypeptide; wherein said inflammatory disease is an inflammatory lung disease, an inflammatory bowel disease, systemic lupus erythematosis, rheumatoid arthritis, idiopathic pulmonary fibrosis, septic shock or multiple organ failure.

    摘要翻译： 提供了与IL-20多肽结合的可溶性受体的用途，其中IL-20多肽包含选自下组的氨基酸序列：SEQ ID NO：1,2,3,4,5,6， 7,8和9，用于制备用于治疗炎性疾病的药物，其中所述可溶性受体包含：第一亚基，所述第一亚基包含选自SEQ ID NO：11,12,55,63的氨基酸序列和 65或其与IL-20多肽结合的片段; 和第二亚基，所述第二亚单位包含选自SEQ ID NO：14,15,19,59,61,67,68和69的氨基酸序列或其与IL-20多肽结合的片段; 其中所述炎性疾病是炎症性肺病，炎症性肠病，系统性红斑狼疮，类风湿性关节炎，特发性肺纤维化，败血性休克或多器官衰竭。

    Mammalian secretory peptide 9, antibodes against it and their use
    5.
    发明公开
    Mammalian secretory peptide 9, antibodes against it and their use 失效
    分泌Peptir-9在哺乳动物中，抗体针对的与所使用

    公开(公告)号：EP1323823A2

    公开(公告)日：2003-07-02

    申请号：EP03002314.7

    申请日：1998-07-02

    申请人： Zymogenetics Inc

    发明人： Sheppard, Paul O. ,  Jaspers, Stephen R. ,  Jelinek, Laura J. ,  Whitmore, Theodore E.

    IPC分类号： C12N15/11 ,  C07K16/18 ,  C07K16/42 ,  A61K38/17 ,  C12Q1/68 ,  G01N33/574

    CPC分类号： C07K14/47 ,  A61K38/00 ,  A61K39/00 ,  C07K2319/00

    摘要： Antibodies, antibody fragments or single chain antibodies that specifically bind to human and mouse orthologs of the Zsig-9 secreted polypeptide are provided, the antibodies are preferably monoclonal. Also provided are methods of using the antibodies of the invention as well as in-vitro methods of diagnosing cancer in human tissues or body fluids utilising the antibodies of the invention or antisense nucleic acid sequences that specifically bind to Zsig-9 polynucleotide sequences. The invention is of particular use in diagnosing cancers such as brain tumour, liver tumour, lung tumour, esophageal tumour, stomach tumour, colon tumour, rectal tumour, thyroid tumour, or lymphoma tumour.

    摘要翻译： 抗体，抗体片段或单链抗体并以设置在ZSIG-9分泌的多肽的人类和小鼠直系同源物特异性结合，所述抗体优选是单克隆的。 所以提供了使用本发明的抗体以及在体外在人组织或利用本发明或反义核酸序列的抗体体液诊断癌症的方法都特异性结合ZSIG-9的序列的多核苷酸的方法。 本发明是在诊断癌症特别有用的：如脑肿瘤，肝肿瘤，肺肿瘤，食管肿瘤，胃肿瘤，结肠肿瘤，直肠肿瘤，甲状腺瘤，或淋巴瘤肿瘤。

    IL-21 antagonists
    6.
    发明公开
    IL-21 antagonists 审中-公开
    IL-21拮抗剂

    公开(公告)号：EP2805971A1

    公开(公告)日：2014-11-26

    申请号：EP14163892.4

    申请日：2006-11-28

    申请人： ZymoGenetics, Inc.

    发明人： Jaspers, Stephen R. ,  Sivakumar, Pallavur V.

    IPC分类号： C07K16/24 ,  A61K39/00 ,  C07K14/54

    CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/30 ,  Y10S530/809

    摘要： Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.

    IL-21 antagonists
    8.
    发明公开
    IL-21 antagonists 无效
    IL-21-Antagonisten

    公开(公告)号：EP2567973A2

    公开(公告)日：2013-03-13

    申请号：EP12192046.6

    申请日：2006-11-28

    申请人： Zymogenetics, Inc.

    发明人： Sivakumar, Pallavur V. ,  Jaspers, Stephen R.

    IPC分类号： C07K16/24 ,  A61K39/00 ,  C07K14/54

    CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/30 ,  Y10S530/809

    摘要： Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.

    摘要翻译： 鉴定结合IL-21蛋白的单克隆抗体。 这些抗体用于鉴定结合中和IL-21活性的IL-21蛋白的区域。 描述了杂交瘤和产生抗IL-21单克隆抗体的方法。 单克隆抗体可用于治疗IL-21介导的疾病，其可能包括自身免疫性和炎性疾病如胰腺炎，I型糖尿病（IDDM），格雷夫斯病，炎性肠病（IBD），克罗恩病，溃疡性结肠炎，肠易激综合征 综合征，多发性硬化症，类风湿性关节炎，憩室炎，系统性红斑狼疮，牛皮癣，强直性脊柱炎，硬皮病，系统性硬化症，牛皮癣关节炎，骨关节炎，特应性皮炎，白癜风，移植物抗宿主病（GVHD），皮肤T细胞淋巴瘤 ，干燥综合征，肾小球性肾炎，IgA肾病，移植物宿主病，移植排斥反应，特应性皮炎，抗磷脂综合征，哮喘和其他自身免疫性疾病。